NCT00742560
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Cancer, +15 more
- Locations
-
Not specified
Clinical trial condition
Hemostatic Disorders
Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.
3,079 public trials
581 recruiting studies
Hemostatic Disorders trial results
NCT00619645
- Conditions
- Anemia, Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, +49 more
- Locations
-
- University of California Davis Cancer Center Sacramento, California, United States
NCT00963820
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
- Locations
-
- Mayo Clinic- Scottsdale Scottsdale, Arizona, United States
- James R. Berenson, MD, Inc West Hollywood, California, United States
- University of Chicago Chicago, Illinois, United States
- Mayo Clinic Rochester, Minnesota, United States
NCT02363439
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
Not specified
Completed
Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma
NCT02220608
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
- Locations
-
- Washington University School of Medicine St Louis, Missouri, United States
NCT00867529
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, +83 more
- Locations
-
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
Completed
Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients
NCT01270932
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Female Urogenital Diseases, +20 more
- Locations
-
- University Health Network- Princess Margaret Hosptial Toronto, Ontario, Canada
NCT00422656
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
- Locations
-
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
Completed
Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
NCT01083602
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +19 more
- Locations
-
- University of California at Los Angeles Los Angeles, California, United States
- Stanford University Medical Center Division of Hematology Stanford, California, United States
- H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States
- Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst. Atlanta, Georgia, United States
Completed
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00461045
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
- Locations
-
- Moffitt Cancer Center Tampa, Florida, United States
- University of Chicago, School of Medicine Chicago, Illinois, United States
- University of Maryland Baltimore, Maryland, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States